长效卡博特韦联合利匹韦林治疗HIV:现状与挑战
本叙述性综述综合同行评议文献与国际会议证据,评估长效注射卡博特韦联合利匹韦林(LAI CAB+RPV)在真实临床实践中的有效性与安全性。真实世界队列显示病毒学抑制率通常>90%,确认病毒学失败率低,注射部位反应常见但很少导致停药。随访期短和样本量小限制了对女性、老年人、高BMI及跨性别者等亚组的结论。
要点
- LAI CAB+RPV为病毒学抑制的HIV感染者提供替代每日口服ART的选项。
- 真实世界队列病毒学抑制率通常>90%,确认病毒学失败率低。
- 注射部位反应常见但很少导致停药,总体耐受性高。
核心结论
- LAI CAB+RPV是维持病毒学抑制的有前景且耐受性良好的选择,可能满足广泛HIV感染者的未满足需求。
研究设计与样本
- 叙述性综述,综合同行评议出版物和主要国际HIV会议的最新证据。
主要发现
- 近期真实世界队列研究一致报告病毒学抑制率高(通常>90%),确认病毒学失败率低。
- 注射部位反应常见但很少导致停药,总体耐受性高。
- 有非依从史者在适当支持系统下也可成功实施LAI CAB+RPV。
关键数值与推荐
- 病毒学抑制率通常>90%。
- 确认病毒学失败率低。
临床怎么用
- 可用于病毒学抑制的HIV感染者,包括有非依从史者,但需适当支持系统。
- 需关注女性、老年人、高BMI者和跨性别者等亚组的有限数据。
局限性
- 当前数据受随访期短和样本量相对较小限制。
- 女性、老年人、高BMI者或跨性别者等代表性不足群体的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-acting injectable cabotegravir plus rilpivirine (LAI CAB + RPV) represents an important advance in HIV treatment, offering an alternative to daily oral antiretroviral therapy (ART) for people with HIV (PWH) who are virologically suppressed. This narrative review aims to (i) evaluate the effectiveness and safety of LAI CAB + RPV in real-world clinical practice; (ii) assess outcomes in key subgroups, including women, older adults, people with elevated BMI, transgender people, and those with adherence challenges; and (iii) discuss practical and implementation considerations relevant to routine care. We synthesized the most up-to-date evidence from peer-reviewed publications and major international HIV conferences. Recent real-world cohort studies consistently report high rates of virological suppression (typically >90%) and low rates of confirmed virological failure, even in diverse populations and those with complex social or medical needs. Injection site reactions are common but rarely lead to discontinuation, and overall tolerability is high. Evidence suggests that LAI CAB + RPV can be successfully implemented in clinical practice, including among individuals with a history of non-adherence, provided that appropriate support systems are in place. However, current data are limited by short follow-up periods and relatively small sample sizes, especially in underrepresented groups such as women, older adults, people with high BMI, or transgender people. Further research is needed to clarify long-term outcomes and optimize patient selection. In summary, LAI CAB + RPV is a promising and well-tolerated option for maintaining virological suppression in routine care, with the potential to address important unmet needs across a broad spectrum of PWH. Ongoing studies will help define its optimal use and long-term benefits in real-world settings.
引用
- Buzón-Martín L, Cabello A, Díaz de Santiago A, et al. Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead. J Antimicrob Chemother. 2025. PMID: 40794804. doi:10.1093/jac/dkaf246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。